IS7096A - Setin úreataugapeptíð Y Y5 viðtakamótlyf - Google Patents
Setin úreataugapeptíð Y Y5 viðtakamótlyfInfo
- Publication number
- IS7096A IS7096A IS7096A IS7096A IS7096A IS 7096 A IS7096 A IS 7096A IS 7096 A IS7096 A IS 7096A IS 7096 A IS7096 A IS 7096A IS 7096 A IS7096 A IS 7096A
- Authority
- IS
- Iceland
- Prior art keywords
- urothelial
- peptide
- replaced
- receptor antagonists
- antagonists
- Prior art date
Links
- 102100029549 Neuropeptide Y receptor type 5 Human genes 0.000 title 1
- 101710198055 Neuropeptide Y receptor type 5 Proteins 0.000 title 1
- 101710117971 Peptide Y Proteins 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30843301P | 2001-07-26 | 2001-07-26 | |
| PCT/US2002/023552 WO2003009845A1 (en) | 2001-07-26 | 2002-07-24 | Substituted urea neuropeptide y y5 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IS7096A true IS7096A (is) | 2003-12-31 |
Family
ID=23193972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS7096A IS7096A (is) | 2001-07-26 | 2003-12-31 | Setin úreataugapeptíð Y Y5 viðtakamótlyf |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6667319B2 (is) |
| EP (1) | EP1418913A1 (is) |
| JP (1) | JP2005500338A (is) |
| CN (2) | CN1911913A (is) |
| AR (1) | AR036191A1 (is) |
| AU (1) | AU2002355286B2 (is) |
| CA (1) | CA2454830C (is) |
| HU (1) | HUP0401643A3 (is) |
| IL (1) | IL159643A0 (is) |
| IS (1) | IS7096A (is) |
| MX (1) | MXPA04000707A (is) |
| NZ (1) | NZ530429A (is) |
| PE (1) | PE20030385A1 (is) |
| PL (1) | PL368201A1 (is) |
| TW (1) | TWI300064B (is) |
| WO (1) | WO2003009845A1 (is) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0121709D0 (en) * | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| PL205971B1 (pl) * | 2001-09-24 | 2010-06-30 | Imp Innovations Ltd | Zastosowanie PYY₃-₃₆ do wytwarzania leku na ograniczanie apetytu, zmniejszenie otyłości lub do zapobiegania otyłości |
| US8058233B2 (en) | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
| US7166575B2 (en) * | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
| GB0300571D0 (en) * | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| CA2520763A1 (en) | 2003-04-03 | 2004-10-21 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
| JP2007532484A (ja) | 2004-03-16 | 2007-11-15 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 可溶性エポキシド加水分解酵素の阻害剤およびエポキシエイコサノイドを用いて腎症を緩和する方法 |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| TW200630337A (en) * | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| WO2006045119A2 (en) | 2004-10-20 | 2006-04-27 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
| FR2884516B1 (fr) * | 2005-04-15 | 2007-06-22 | Cerep Sa | Antagonistes npy, preparation et utilisations |
| GB0511986D0 (en) * | 2005-06-13 | 2005-07-20 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| NZ564758A (en) * | 2005-06-30 | 2011-03-31 | Prosidion Ltd | G-protein coupled receptor agonists |
| FR2894964B1 (fr) * | 2005-12-19 | 2008-02-22 | Cerep Sa | Composes a base de quatre cycles aromatiques, preparation et utilisations |
| AR059826A1 (es) * | 2006-03-13 | 2008-04-30 | Univ California | Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble |
| WO2007110449A1 (en) | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
| TW200812963A (en) | 2006-04-13 | 2008-03-16 | Euro Celtique Sa | Benzenesulfonamide compounds and the use thereof |
| TW200815353A (en) | 2006-04-13 | 2008-04-01 | Euro Celtique Sa | Benzenesulfonamide compounds and their use |
| WO2008026564A1 (fr) * | 2006-08-30 | 2008-03-06 | Shionogi & Co., Ltd. | Dérivés d'urée |
| TWI428346B (zh) * | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| US8399486B2 (en) * | 2007-04-09 | 2013-03-19 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use thereof |
| ES2393885T7 (es) | 2007-06-04 | 2014-01-30 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| US8765736B2 (en) | 2007-09-28 | 2014-07-01 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| ES2522968T3 (es) | 2008-06-04 | 2014-11-19 | Synergy Pharmaceuticals Inc. | Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| AU2009270833B2 (en) | 2008-07-16 | 2015-02-19 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| MX2011004258A (es) | 2008-10-22 | 2011-06-01 | Merck Sharp & Dohme | Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos. |
| CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US9296693B2 (en) | 2010-01-29 | 2016-03-29 | The Regents Of The University Of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
| CA2786314A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| KR101668514B1 (ko) | 2011-02-25 | 2016-10-21 | 머크 샤프 앤드 돔 코포레이션 | 항당뇨병제로서 유용한 신규 시클릭 아자벤즈이미다졸 유도체 |
| CN102675190A (zh) * | 2012-05-23 | 2012-09-19 | 盛世泰科生物医药技术(苏州)有限公司 | 一种3-（二甲氨基）次甲基-n-甲磺酰基哌啶-4-酮的合成方法 |
| JP2015525782A (ja) | 2012-08-02 | 2015-09-07 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗糖尿病性三環式化合物 |
| RU2015140066A (ru) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | Противодиабетические бициклические соединения |
| US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
| CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
| US10011637B2 (en) | 2013-06-05 | 2018-07-03 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| US10968232B2 (en) | 2016-12-20 | 2021-04-06 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| CA3087729A1 (en) | 2018-01-11 | 2019-07-18 | Centaurus Therapeutics | Inhibitors of dihydroceramide desaturase for treating disease |
| WO2022076365A1 (en) * | 2020-10-06 | 2022-04-14 | Eastman Chemical Company | Aromatic enol ethers |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2928485A1 (de) | 1979-07-14 | 1981-01-29 | Bayer Ag | Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen |
| US4623662A (en) | 1985-05-23 | 1986-11-18 | American Cyanamid Company | Antiatherosclerotic ureas and thioureas |
| US5602024A (en) | 1994-12-02 | 1997-02-11 | Synaptic Pharmaceutical Corporation | DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof |
| CN1311773A (zh) | 1998-06-08 | 2001-09-05 | 先灵公司 | 神经肽y5受体拮抗剂 |
| DE69929235T2 (de) | 1998-11-10 | 2006-08-24 | Merck & Co., Inc. | Spiro-indole als y5-rezeptor antagonisten |
| EP1322628A2 (en) | 2000-09-14 | 2003-07-02 | Schering Corporation | Substituted urea neuropeptide y y5 receptor antagonists |
-
2002
- 2002-07-24 MX MXPA04000707A patent/MXPA04000707A/es active IP Right Grant
- 2002-07-24 HU HU0401643A patent/HUP0401643A3/hu unknown
- 2002-07-24 PE PE2002000653A patent/PE20030385A1/es not_active Application Discontinuation
- 2002-07-24 IL IL15964302A patent/IL159643A0/xx unknown
- 2002-07-24 CN CNA2006101215468A patent/CN1911913A/zh active Pending
- 2002-07-24 JP JP2003515237A patent/JP2005500338A/ja active Pending
- 2002-07-24 AR ARP020102785A patent/AR036191A1/es unknown
- 2002-07-24 EP EP02752562A patent/EP1418913A1/en not_active Withdrawn
- 2002-07-24 CN CNA028189647A patent/CN1558764A/zh active Pending
- 2002-07-24 PL PL02368201A patent/PL368201A1/xx not_active Application Discontinuation
- 2002-07-24 CA CA002454830A patent/CA2454830C/en not_active Expired - Fee Related
- 2002-07-24 AU AU2002355286A patent/AU2002355286B2/en not_active Ceased
- 2002-07-24 NZ NZ530429A patent/NZ530429A/en unknown
- 2002-07-24 TW TW091116480A patent/TWI300064B/zh active
- 2002-07-24 WO PCT/US2002/023552 patent/WO2003009845A1/en active IP Right Grant
- 2002-07-24 US US10/202,239 patent/US6667319B2/en not_active Expired - Fee Related
-
2003
- 2003-10-24 US US10/692,559 patent/US7304076B2/en not_active Expired - Fee Related
- 2003-12-31 IS IS7096A patent/IS7096A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR036191A1 (es) | 2004-08-18 |
| US6667319B2 (en) | 2003-12-23 |
| NZ530429A (en) | 2005-09-30 |
| EP1418913A1 (en) | 2004-05-19 |
| JP2005500338A (ja) | 2005-01-06 |
| WO2003009845A1 (en) | 2003-02-06 |
| CA2454830A1 (en) | 2003-02-06 |
| WO2003009845A9 (en) | 2004-03-11 |
| CN1558764A (zh) | 2004-12-29 |
| CN1911913A (zh) | 2007-02-14 |
| AU2002355286B2 (en) | 2005-10-13 |
| PL368201A1 (en) | 2005-03-21 |
| MXPA04000707A (es) | 2004-04-20 |
| US20030207860A1 (en) | 2003-11-06 |
| TWI300064B (en) | 2008-08-21 |
| US7304076B2 (en) | 2007-12-04 |
| HUP0401643A2 (hu) | 2004-12-28 |
| HUP0401643A3 (en) | 2009-06-29 |
| US20040102474A1 (en) | 2004-05-27 |
| CA2454830C (en) | 2010-02-02 |
| PE20030385A1 (es) | 2003-05-08 |
| IL159643A0 (en) | 2004-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IS7096A (is) | Setin úreataugapeptíð Y Y5 viðtakamótlyf | |
| DE60136562D1 (de) | Heteroaryl-harnstoff-neuropeptid-y-y5-rezeptor-antagonisten | |
| ATE525378T1 (de) | Himbacinanaloga als thrombinrezeptorantagonisten | |
| ATE368659T1 (de) | Thrombinrezeptorantagonisten | |
| CY2015029I1 (el) | Τρικυκλικοι ανταγωνιστες υποδοχεα θρομβινης | |
| NO20032612L (no) | CXCR3-antagonister | |
| IS8482A (is) | Kalsítóníngen-skyldir peptíðviðtaka antagónistar | |
| NO20051871D0 (no) | Opioid reseptorantagonister | |
| ATE413400T1 (de) | Cgrp-rezeptorantagonisten | |
| DE602004030930D1 (de) | Muscarinische acetylcholin-rezeptor-antagonisten | |
| NO20050429D0 (no) | Substituert kinolin-CCR5-reseptorantagonister | |
| IS2790B (is) | Mótefni gegn viðtaka insúlínlíks vaxtarþáttar af gerð I | |
| DK1682142T3 (da) | M3-muscarin-acetylcholin-receptor-antagonister | |
| ATE400558T1 (de) | Metabotropische glutamatrezeptor-antagonisten | |
| AU2003251739A8 (en) | New neuropeptide y y5 receptor antagonists | |
| DE602004004278D1 (de) | 4-cycloalkylaminopyrazolopyrimidin als nmda/nr2b-antagonisten | |
| ATE403651T1 (de) | 3-fluoro-piperidine als nmda/nr2b antagonisten | |
| ATE469875T1 (de) | Nk1-antagonisten | |
| DE60222693D1 (de) | Nk1-antagonisten | |
| ATE370114T1 (de) | Zwitterionische tachykinin-rezeptor-antagonisten | |
| DK1372688T3 (da) | Somatostatin-antagonister | |
| DE50100358D1 (de) | Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten | |
| ATE418542T1 (de) | Als ccr5-antagonisten verwendbare aryloxim- piperazine | |
| NO20032963D0 (no) | Peptidforbindelser | |
| ATE370932T1 (de) | Ccr-3-rezeptorantagonisten vii |